Tumor cells (red) grown within a microstructure (host tissue; green), a...
Tumor cells (red) grown within a microstructure (host tissue; green), a so-called organoid. The Rubin Lab has been developing organoids that will serve as a tool for investigating patient-derived tumors at a cell-cell level.

© Alison Ferguson / BCPM

News • Precision oncology

What's new in cancer therapy?

Researchers from the University of Bern and Inselspital provide an overview of the latest technologies in precision oncology. Translating these into clinical application is still a major challenge.

portrait of mark rubin
Prof. Mark A. Rubin

© University of Bern, Image: Vera Knöpfel

Tumors have significant differences depending on the person affected, even if they are the same cancer, such as breast cancer. Therefore, precision oncology targets specific genetic characteristics of a tumor and incorporates them into treatment. In this way, existing therapies can be "tailored" to avoid side effects and save money on expensive treatments. 

Dr Dilara Akhoundova, medical oncologist at the University Hospital Bern and postdoctoral researcher at the University of Bern, and Prof Mark A. Rubin, director of the Department for BioMedical Research (DBMR) and the Bern Center for Precision Medicine (BCPM), have now summarized and reviewed the most recent advances in multi-omics tumor profiling. In their review, published in the journal Cancer Cell, they provide a critical view of the current state of translational validation of the reviewed technologies and analyze their potential for integration into precision treatment. “These new technologies take us to a depth of understanding of tumors that has never been seen before. It is as if with the standard tools, we were told that Switzerland is a country with higher altitudes than the Netherlands; with these new technologies, we can see the 3D landscape of mountains, valleys, and lakes,” says Rubin.

However, there are still a number of hurdles to overcome before the latest technologies can be used in the clinic: among other things, they still need to be standardized, or require new infrastructures in clinics due to the evaluation of a very large volume of data or regulatory approval. 

One of the latest promising technologies in precision oncology is liquid biopsy, which makes it possible to provide information about the type of cancer in patients more quickly and minimally invasively by means of a blood test. Especially in the case of tumors located deep in the body, such as in the lungs or pancreas, this requires invasive procedures, occasionally under general anesthesia. Many such technologies as liquid biopsy are being used in translational and clinical cancer research. Their clinical potential is already very high; they still require, in some cases, an additional method that increases measurement accuracy for certain samples. Other innovations are still in their infancy and need to be clinically validated to see if they can even achieve their goal.

Recommended article

portrait of Dilara Akhoundova
Dr. Dilara Akhoundova

© Courtesy of Dilara Akhoundova 

Advancing and implementing novel, cutting-edge technologies into precision medicine is a crucial focus of BCPM. Cancer translational research projects led by researchers at the BCPM, such as those led by Prof. Mark A. Rubin, Prof. Marianna Kruithof-De Julio, and Prof. Sven Rottenberg, as well as a tight collaboration with clinical oncologists from the University Hospital Bern and other Swiss institutions, are essential to advance precision oncology further, and approach novel technologies to the patients. “In our review, we consider how these new approaches can be translated into tests that can better predict responses to tumor therapies in patients," says Dilara Akhoundova, lead author of the study. 

Another important Bern precision oncology initiative is the Swiss Oncology and Cancer Immunology Breakthrough Platform (SOCIBP), which aims to establish a common genomic "language" for Swiss cancer research: Molecular tumor data will be presented and shared in an understandable way, and genomic testing across Switzerland will be standardized. The project is funded by the Swiss Personalized Health Network (SPHN), a federal initiative. “One of our current translational projects focuses on the standardization and clinical validation of genomic tests assessing DNA repair in prostate cancer and other solid tumors”, Rubin explains. The project’s overarching goal is to develop more reliable predictive biomarkers allowing precision oncology treatment for tumors harboring DNA repair defects. 

Source: University of Bern


Related articles


News • Precision oncology

Genomic sequencing benefits only 5% of cancer patients

Genomic sequencing panels as part of personalised cancer treatment have been found to only benefit one in 20 patients they are currently used for, according to a study by CNIO.


Article • Progress, limitations, and opportunities

Precision oncology: incredible potential, but not a miracle cure

Unanswered questions are hampering clinicians in their efforts to get the best out of a precision medicine approach for their patients. Speaking at the Genomics and Precision Medicine Expo in London…


News • Targeted therapy

Biliary duct cancer: the future of precision oncology

Gene alterations in biliary tract cancer offer potential targets for current or future precision therapies. This is demonstrated by a new study from Vienna.

Related products

Subscribe to Newsletter